Back to search
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) trials you may qualify forBackground: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. \[18F\]FAPI…
This is a single-arm, multicenter phase Ⅱ study to evaluate the therapeutic efficacy and safety of chidamide + sintilimab + bevacizumab in subjects with advance…
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Sma…
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacoki…
This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologo…
To explore the Objective Response Rate (ORR) of Benmelstobart combined with Anlotinib and chemotherapy as first-line treatment for large-cell neuroendocrine car…